Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Skeeter Bug who wrote (30018)	1/9/2000 3:59:00 PM
From: Henry Niman	Respond to of 32384

After reading through the FDA transcript, I think that virtually any vote was possible. However, i think that LGND has had quite a bit of experience dealing with the Agency, and they did get them to see the light with an approval for early and advanced disease. From reading the patient testimonials, I would think that targretin will be used as the first systemic therapy in many cases, and the positive news for CTCL patients will spill over into the psoriasis population.